A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.

  • Hoelscher M
  • Singh N
  • Garg S
 et al. 
  • 30


    Mendeley users who have this article in their library.
  • 47


    Citations of this article.


Development of effective and immunogenic vaccines against highly pathogenic avian influenza H5N1 viruses with the potential to cause a pandemic is a public health priority. The global demand for a vaccine cannot be met in the event of an influenza pandemic because of the limited capacity to manufacture egg-derived vaccines as well as potential problems with the availability of embryonated eggs. Thus, there is an urgent need to develop alternative, egg-independent vaccines. We developed an adenoviral vector-based vaccine that contains hemagglutinin protein from clade 1 and clade 2 viruses, as well as conserved nucleoprotein, to broaden the vaccine coverage against H5N1 viruses.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Mary A Hoelscher

  • Neetu Singh

  • Sanjay Garg

  • Lakshmi Jayashankar

  • Vic Veguilla

  • Aseem Pandey

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free